Drugs / fluticasone proprionate
last change Oct 2024 re-read 2 minutes ago

fluticasone proprionate

Other / unclassified

Developed for
asthma · vitiligo
Investigated by
Allergy and Asthma Center of El Paso · GlaxoSmithKline · Hvidovre University Hospital

Trials 2 · a red edge is where a trial was stopped

2009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 4 NCT03141424 Jun 2022 → Oct 2024 asthma Hvidovre University Hospital Completed No outcome recorded
Phase 4 NCT00867737 Sep 2008 → Sep 2009 asthma Allergy and Asthma Center of El Paso Unknown No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 31 trial
Phase 3 NCT03376932 Comparator Jan 2019 → Feb 2021 asthma GlaxoSmithKline Withdrawn No outcome recorded
Phase 41 trial
Phase 4 NCT01246921 Comparator Sep 2009 → Aug 2011 vitiligo Academic Medical Center - University of Amsterdam Unknown No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Fluticasone proprionate “Effectiveness of Fluticasone Furoate/ Umeclidinium/ Vilanterol (FF/UMEC/VI) Using the Connected Inhaler System (CIS) as Compared With Fluticasone Proprionate/ Salmeterol...” NCT03376932
3

“Advair = fluticasone proprionate plus salmeterol” NCT00867737

fluticasone proprionateNCT03141424

NCT01246921

Modality Other / unclassified “inhaled corticosteroid (ICS) treatment” NCT03141424
Route Inhaled “Two puffs from MDI twice daily for 4 weeks” NCT00867737